Samuel S Gidding1, Fida Bacha2, Petter Bjornstad3, Lorraine E Levitt Katz4, Lynne L Levitsky5, Jane Lynch6, Jeanie B Tryggestad7, Ruth S Weinstock8, Laure El Ghormli9, Joao A C Lima10. 1. Nemours Cardiac Center, Alfred I. DuPont Hospital for Children, Wilmington, DE. 2. Texas Children's Hospital, Baylor College of Medicine, Houston, TX. 3. University of Colorado Anschutz Medical Campus and Children's Hospital Colorado, Aurora, CO. 4. Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. 5. Massachusetts General Hospital, Boston, MA. 6. University of Texas Health Science Center San Antonio, San Antonio, TX. 7. University of Oklahoma Health Sciences Center, Oklahoma, OK. 8. Department of Medicine, SUNY Upstate Medical University, Syracuse, NY. 9. George Washington University Biostatistics Center, Rockville, MD. Electronic address: elghorml@bsc.gwu.edu. 10. Johns Hopkins Hospital, Johns Hopkins University, Baltimore, MD.
Abstract
OBJECTIVES: To examine cardiac biomarkers over time in youth-onset type 2 diabetes, and relate serum concentrations to cardiovascular disease risk factors, and left ventricular structure and function. STUDY DESIGN: TODAY (Treatment Options for type 2 Diabetes in Adolescents and Youth) was a multicenter randomized trial of 3 treatments including 521 participants with type 2 diabetes, aged 10-17 years, and with 2-6 years of follow-up. Participants were 36% male, obese, and ethnically diverse. Annual serum concentrations of brain natriuretic peptide, troponin, tumor necrosis factor (TNF)-α, receptors 1 and 2 were related to blood pressure, body mass index, hemoglobin A1c, and left ventricular ejection fraction, diastolic function, relative wall thickness, and mass. RESULTS:Elevated concentrations of brain natriuretic peptide (≥100 pg/mL), TNF-α (≥5.6 pg/mL) and troponin (≥0.01 ng/mL), were present in 17.8%, 18.3%, and 34.2% of the cohort, respectively, at baseline, and in 15.4%, 17.1%, and 31.1% at the end of the study, with wide variability over time, without persistence in individuals or clear relationship to glycemia or cardiovascular structure/function. TNF receptors concentrations were increased at baseline and not significantly different from end-of-study concentrations. Adverse echocardiographic measures were more likely in the highest TNF receptor tertile (all P < .05): higher left ventricular mass (39.3 ± 9.0 g/m2.7), left atrial internal dimension (3.7 ± 0.4 cm) and E/Em ratio, a measure of diastolic dysfunction (6.2 ± 1.9). After adjustment for body mass index, these relationships were no longer significant. CONCLUSIONS: Elevated serum concentrations of cardiac biomarkers were common in youth with type 2 diabetes, but their clinical significance is unclear and will require further long-term study. TRIAL REGISTRATION: ClinicalTrials.govNCT00081328.
RCT Entities:
OBJECTIVES: To examine cardiac biomarkers over time in youth-onset type 2 diabetes, and relate serum concentrations to cardiovascular disease risk factors, and left ventricular structure and function. STUDY DESIGN: TODAY (Treatment Options for type 2 Diabetes in Adolescents and Youth) was a multicenter randomized trial of 3 treatments including 521 participants with type 2 diabetes, aged 10-17 years, and with 2-6 years of follow-up. Participants were 36% male, obese, and ethnically diverse. Annual serum concentrations of brain natriuretic peptide, troponin, tumor necrosis factor (TNF)-α, receptors 1 and 2 were related to blood pressure, body mass index, hemoglobin A1c, and left ventricular ejection fraction, diastolic function, relative wall thickness, and mass. RESULTS: Elevated concentrations of brain natriuretic peptide (≥100 pg/mL), TNF-α (≥5.6 pg/mL) and troponin (≥0.01 ng/mL), were present in 17.8%, 18.3%, and 34.2% of the cohort, respectively, at baseline, and in 15.4%, 17.1%, and 31.1% at the end of the study, with wide variability over time, without persistence in individuals or clear relationship to glycemia or cardiovascular structure/function. TNF receptors concentrations were increased at baseline and not significantly different from end-of-study concentrations. Adverse echocardiographic measures were more likely in the highest TNF receptor tertile (all P < .05): higher left ventricular mass (39.3 ± 9.0 g/m2.7), left atrial internal dimension (3.7 ± 0.4 cm) and E/Em ratio, a measure of diastolic dysfunction (6.2 ± 1.9). After adjustment for body mass index, these relationships were no longer significant. CONCLUSIONS: Elevated serum concentrations of cardiac biomarkers were common in youth with type 2 diabetes, but their clinical significance is unclear and will require further long-term study. TRIAL REGISTRATION: ClinicalTrials.govNCT00081328.
Authors: Fred S Apple; Curtis A Parvin; Kenneth F Buechler; Robert H Christenson; Alan H B Wu; Allan S Jaffe Journal: Clin Chem Date: 2005-11 Impact factor: 8.327
Authors: David M Maahs; Stephen R Daniels; Sarah D de Ferranti; Helén L Dichek; Joseph Flynn; Benjamin I Goldstein; Aaron S Kelly; Kristen J Nadeau; Pamela Martyn-Nemeth; Stavroula K Osganian; Laurie Quinn; Amy S Shah; Elaine Urbina Journal: Circulation Date: 2014-08-28 Impact factor: 29.690
Authors: Maria H Kroon; Katja van den Hurk; Marjan Alssema; Otto Kamp; Coen D A Stehouwer; Ronald M A Henry; Michaela Diamant; Frans Boomsma; Giel Nijpels; Walter J Paulus; Jacqueline M Dekker Journal: Diabetes Care Date: 2012-10-01 Impact factor: 19.112
Authors: E M Venditti; K Tan; N Chang; L Laffel; G McGinley; N Miranda; J B Tryggestad; N Walders-Abramson; P Yasuda; L Delahanty Journal: Diabetes Res Clin Pract Date: 2018-02-08 Impact factor: 5.602
Authors: Ida Pastore; Andrea Mario Bolla; Laura Montefusco; Maria Elena Lunati; Antonio Rossi; Emma Assi; Gian Vincenzo Zuccotti; Paolo Fiorina Journal: Int J Mol Sci Date: 2020-07-12 Impact factor: 5.923